Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/1/2020
SIETES contiene 92882 citas

 
 
 1 a 6 de 6 
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. Lancet 2020;395:11 de enero. [Ref.ID 103504]
2. Cita con resumen
Chlebowski RT. IBIS-I tamoxifen update: maturity brings questions. Lancet Oncol 2015;16:7-9. [Ref.ID 98773]
3.Enlace a cita original Cita con resumen
Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, on behalf of the IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015;16:67-75. [Ref.ID 98772]
4.Tiene citas relacionadas
Cameron DA. Breast cancer chemoprevention: little progress in practice?. Lancet 2014;383:1018-20. [Ref.ID 97307]
5.Tiene citas relacionadas Cita con resumen
Cuzick J, Sestak I, Forbes JF, Dowsett M, Knox J, Cawthorn S, Saunders Ch, Roche N, Mansel RE, von Minckwitz G, Bonanni B, Palva T, Howell A, on behalf of the IBIS-II investigators. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014;383:1041-8. [Ref.ID 97306]
6. Cita con resumen
Thornton H. Medical innovators: time to show some respect. Lancet 2003;361:1911. [Ref.ID 66150]
Seleccionar todas
 
 1 a 6 de 6